Microarrays at NovAliX
Alzheimer’s has been the graveyard for so many would-be drugs. Many big pharma companies have abandoned the race but despite that, there are smaller players with the chutzpah to engage. Someone will succeed eventually. Could it be Cantabio? A recent nature Scientific report from Cantabio scientists and NovAliX describes the identification of small molecules binders of alpha-Synuclein which is overexpressed and becomes aggregation in Parkinson’s disease. The data so far looks promising but there is still a long way to go.
The starting point for Cantabio’s drug discovery efforts came from NovAliX’s small-molecule microarray technology. This unique SPR based approach is ideally suited to unstable drug discovery targets.